Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study

A. Burger, Jan; M. Barr, Paul; Robak, Tadeusz; Owen, Carolyn; Ghia, Paolo; Tedeschi, Alessandra; Bairey, Osnat; Hillmen, Peter; E. Coutre, Steven; Devereux, Stephen; Grosicki, Sebastian; McCarthy, Helen; Simpson, David; Offner, Fritz; Moreno, Carol; Dai, Sandra; Lal, Indu; P. Dean, James; J. Kipps, Thomas

doi:10.1038/s41375-019-0602-x

Public

Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study

Shared by NobleBlocks on Oct 18, 2019 • 12:00 AM UTC

Authors:

Jan A. Burger

Paul M. Barr

Tadeusz Robak

Abstract

Abstract RESONATE-2 is a phase 3 study of first-line ibrutinib versus chlorambucil in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Patients aged ≥65 years ( n = 269) were randomized 1:1 to once-daily ibrutinib 420 mg continuously or chlorambucil 0.5–0.8 mg/kg for ≤12 cycles. ...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!